CTXR Company Profile and Key Details

Q: Who are the executives of CTXR?

Dr. Myron S. Czuczman M.D.Executive Vice President & Chief Medical OfficerMr. Gary F. TalaricoExecutive Vice President of OperationsMr. Kelly Creighton Ph.D.Executive Vice President of Chemistry, Manufacturing & ControlsMr. Nikolas BurlewExecutive Vice President of Quality AssuranceMr. Myron Z. HolubiakCo-Founder & Executive Vice ChairmanMs. Ilanit AllenVice President of Investor Relations & Corporation CommunicationsMr. Leonard L. MazurCo-Founder, Chief Executive Officer, Chairman & Sec.Mr. Jaime BartushakChief Bus. Officer, Chief Financial Officer & Chief Accounting OfficerDr. Alan Lader Ph.D.Senior Vice President and Head of Clinical Operations & Quality AssuranceMr. Dhananjay G. WadekarSenior Vice President of Bus. Strategy

NASDAQ : CTXR

Citius Pharmaceuticals

$0.72

0.01+1.41%

At Close 4:00 PM

62.22

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Citius Pharmaceuticals, Inc. (CTXR) stock surged +1.41%, trading at $0.72 on NASDAQ, up from the previous close of $0.71. The stock opened at $0.72, fluctuating between $0.72 and $0.75 in the recent session.

Stock Snapshot

0.71

Prev. Close

8.05M

Market Cap

0.7193

Day Low

-0.31

P/E Ratio

-2.31

EPS (TTM)

-0.19

Cash Flow per Share

0.72

Open

11.17M

Number of Shares

0.7498

Day High

94.26%

Free Float in %

0.53

Book Value

269.03K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 25, 2026	0.72	0.75	0.72	0.72	342.13K
Mar 24, 2026	0.74	0.75	0.68	0.71	459.03K
Mar 23, 2026	0.76	0.79	0.72	0.75	467.81K
Mar 20, 2026	0.78	0.80	0.75	0.77	391.67K
Mar 19, 2026	0.80	0.84	0.77	0.81	384.71K
Mar 18, 2026	0.81	0.83	0.76	0.83	633.48K
Mar 17, 2026	0.90	0.95	0.81	0.81	738.77K
Mar 16, 2026	0.96	1.00	0.88	0.88	662.54K
Mar 13, 2026	0.87	1.03	0.86	0.96	1.31M
Mar 12, 2026	0.91	0.94	0.83	0.87	557.29K
Mar 11, 2026	1.02	1.08	0.86	0.91	1.79M
Mar 10, 2026	0.90	0.99	0.86	0.93	1.81M
Mar 09, 2026	0.84	0.88	0.78	0.84	404.13K
Mar 06, 2026	0.95	0.96	0.78	0.84	936.36K
Mar 03, 2026	0.70	0.74	0.67	0.74	359.74K
Mar 02, 2026	0.70	0.73	0.70	0.72	115.96K
Feb 27, 2026	0.75	0.77	0.72	0.74	153.05K
Feb 26, 2026	0.73	0.77	0.73	0.75	209.47K
Feb 25, 2026	0.74	0.75	0.71	0.75	255.47K
Feb 24, 2026	0.67	0.75	0.66	0.75	417.18K

Contact Details

Cranford, NJ 07016

United States

https://www.citiuspharma.com 908 967 6677

About Company

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Stock Peers

REGN

7.78+1.05%

Regeneron Pharmaceuticals, Inc.$749.47 ARGX

19.55+2.89%

argenx SE$697.05 UTHR

9.78+1.84%

United Therapeutics Corporation$541.60 MDGL

16.89+3.80%

Madrigal Pharmaceuticals, Inc.$461.93 VRTX

6.35+1.42%

Vertex Pharmaceuticals Incorporated$454.97 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

20.65+6.70%

Alnylam Pharmaceuticals, Inc.$328.70 PRAX

17.27+5.86%

Praxis Precision Medicines, Inc.$311.92 KRYS

7.86+3.18%

Krystal Biotech, Inc.$254.95 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) closed at $0.72 USD, gaining $0.01 (1.41%) from the previous close of $0.71. The stock is currently mid-range between its 52-week high and low $0.63 and $2.48. With a market capitalization of about $8.05 million, Citius Pharmaceuticals, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.56). Key stats such as the average daily volume over the past year has been around 881.32 thousand shares, volume is running light vs its 52-week average. Headquartered in Cranford, NJ, Citius Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Leonard L. Mazur, the company employs approximately 23 people and listed since October 02, 2014. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 -0.35%, SMA50 -10.4%, SMA200 -34.86%). The stock’s 14-day RSI is 46.67 (neutral), while the ATR of 0.07 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -69.59% below its high and over 19.71% above its low. Average 10-day trading volume of 510.02 thousand shares is in line with the 3-month average of 511.66 thousand, indicating normal recent market interest.

Valuation Metrics

Citius Pharmaceuticals, Inc. trades at a P/E ratio of -0.44, slightly below the S&P 500 average, with a price-to-sales ratio of 2.08 and a price-to-book ratio of 0.2 suggesting the stock is closer to book value. The P/FCF stands at -0.23, also above market averages.

Dividend & Fair Value

Citius Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.22. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Citius Pharmaceuticals, Inc. generated EPS of -$2.89 over the past year. Five-year average earnings growth is 21.29%. The latest quarter delivered EPS of -$0.01. The next quarter is forecast at $0.45. Next year's EPS is expected at $556.25. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $6.00 to $6.00. The high target offers 733.33% upside. The low target suggests 733.33% downside. The mean target is $6.00. This offers 733.33% upside. Citius Pharmaceuticals, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended December 25, 2025, missed forecasts by -97.67%. The prior quarter beat by 233.33%. Over the last six quarters, Apple has recorded several small beats. These include 3850.0% in December 27, 2024.

Shareholding & Insider Activity

Citius Pharmaceuticals, Inc. has 17.01 million shares outstanding. The public float is 16.26 million shares, elevated short interest at 4.81% of float. This equals 795.32 thousand shares. The short ratio is 1.85 days. Institutional investors hold 5.62% of the float. Insiders own 2.9%.

Financial & Profitability Overview

Over the trailing twelve months, Citius Pharmaceuticals has not generated any revenue. Returns are negative, with ROA at -28.59% and ROE at -55.42%.
On valuation metrics, Citius Pharmaceuticals trades at a P/E of -0.44, P/S of 2.08 and P/B of 0.20. Liquidity is tight, with a current ratio of 0.99 and quick ratio of 0.40. Operationally, the company’s inventory turnover is 0.07 and cash conversion cycle is 3160.77 days. Debt-to-equity is 0.02, supported by a cash flow-to-debt ratio of -19.04.

Quarterly Financial Highlights

For the quarter ended Sep 30, 2025, Citius Pharmaceuticals posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $214.25K (margin 0.00%). Operating income was - $38.53M (margin 0.0%). Net income was- $37.43M (EPS - $3.38).
The company ended the quarter with $4.25M in cash and short-term investments, a total debt of $813.27K, and net debt of - $3.44M. Total assets were $130.94M, with equity of $77.53M. Financials further reflected weakness, with operating cash flow of - $26.55M, free cash flow of - $26.55M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Citius Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.94%, with price expected at $0.77 by April 07, 2026, within a range of $0.69 to $0.85 3-Month Outlook: Projected fall of -62.5%, reaching $0.27 by June 22, 2026, with a range of $0.07 to $0.42. 1-Year Outlook: Projected gain of 38.89%, with price at $1.00 by March 24, 2027, within a range of $0.00 to $0.00.

Key Takeaways

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) shares are flat 4.36% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Citius Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -0.44. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $6.19, suggesting 759.72% upside. Our AI forecast model points to short-term strength (6.94% over two weeks), a medium-term fall (-62.5% over three months), and a longer-term gain (38.89% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Citius Pharmaceuticals, Inc. (CTXR) stock price?

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) stock price is $0.72 in the last trading session. During the trading session, CTXR stock reached the peak price of $0.75 while $0.72 was the lowest point it dropped to. The percentage change in CTXR stock occurred in the recent session was 1.41% while the dollar amount for the price change in CTXR stock was $0.01.

CTXR's industry and sector of operation?

The NASDAQ listed CTXR is part of Biotechnology industry that operates in the broader Healthcare sector. Citius Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CTXR?

Dr. Myron S. Czuczman M.D.
Executive Vice President & Chief Medical Officer
Mr. Gary F. Talarico
Executive Vice President of Operations
Mr. Kelly Creighton Ph.D.
Executive Vice President of Chemistry, Manufacturing & Controls
Mr. Nikolas Burlew
Executive Vice President of Quality Assurance
Mr. Myron Z. Holubiak
Co-Founder & Executive Vice Chairman
Ms. Ilanit Allen
Vice President of Investor Relations & Corporation Communications
Mr. Leonard L. Mazur
Co-Founder, Chief Executive Officer, Chairman & Sec.
Mr. Jaime Bartushak
Chief Bus. Officer, Chief Financial Officer & Chief Accounting Officer
Dr. Alan Lader Ph.D.
Senior Vice President and Head of Clinical Operations & Quality Assurance
Mr. Dhananjay G. Wadekar
Senior Vice President of Bus. Strategy

How CTXR did perform over past 52-week?

CTXR's closing price is 14.29% higher than its 52-week low of $0.63 where as its distance from 52-week high of $2.48 is -70.97%.

How many employees does CTXR have?

Number of CTXR employees currently stands at 23.

Link for CTXR official website?

Official Website of CTXR is: https://www.citiuspharma.com

How do I contact CTXR?

CTXR could be contacted at phone 908 967 6677 and can also be accessed through its website. CTXR operates from 11 Commerce Drive, Cranford, NJ 07016, United States.

How many shares of CTXR are traded daily?

CTXR stock volume for the day was 269.03K shares. The average number of CTXR shares traded daily for last 3 months was 881.32K.

What is the market cap of CTXR currently?

The market value of CTXR currently stands at $8.05M with its latest stock price at $0.72 and 11.17M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	23
Beta	1.56
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	September
Sector	Healthcare
Industry	Biotechnology

CTXR Company Profile and Key Details

Citius Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Company Overview

Earnings & Analyst Outlook

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Key Takeaways

Price Forecast & Outlook